[ad_1]
Shares of TherapeuticsMD Inc.
TXMD,
tumbled 41.6% in premarket trading on Wednesday after the women’s health company told investors that EW Healthcare Partners’ planned acquisition of TherapeuticsMD isn’t expected to go through. The tender offer expired Tuesday. TherapeuticsMD, which markets women’s health products like Bijuva and Imvexxy for women in menopause, said it will “maintain normal operations at this time.” The private equity firm said May 31 that it planned to buy TherapeuticsMD for $177 million. The company’s stock is down 53.4% this year, while the broader S&P 500
SPX,
has declined 19.9%.
[ad_2]
Source link
